Table 1.
Characteristics of the Study Population
| SARS-CoV-2 Exposed, Uninfected (n = 74) | SARS-CoV-2 Infected Without Respiratory Symptoms (n = 98) | SARS-CoV-2 Infected With Respiratory Symptoms (n = 113) |
P a | ||||
|---|---|---|---|---|---|---|---|
| No. (or Median) | % (or IQR) | No. (or Median) | % (or IQR) | No. (or Median) | % (or IQR) | ||
| Age, years | 9.5 | (5.1–15.8) | 9.3 | (4.8–13.2) | 14.1 | (6.3–17.5) | .01 |
| Female sex | 37 | 50% | 53 | 54% | 59 | 52% | .87 |
| Race/ethnicity | <.0001 | ||||||
| Black or African-American | 2 | 3% | 6 | 6% | 8 | 7% | |
| Latino or Hispanic-American | 42 | 57% | 86 | 88% | 100 | 88% | |
| Non-Hispanic White | 30 | 41% | 6 | 6% | 5 | 4% | |
| Comorbiditiesb | |||||||
| Asthma | 8 | 11% | 6 | 6% | 9 | 8% | .53 |
| Obesity (BMI ≥95th percentile for age) | 20 | 27% | 24 | 24% | 40 | 35% | .19 |
| Environmental tobacco smoke in home | 11 | 15% | 9 | 9% | 14 | 12% | .51 |
| Receipt of antibiotic in prior 30 days | 1 | 1% | 2 | 2% | 3 | 3% | >.99 |
| Receipt of probiotic in prior 30 days | 3 | 4% | 0 | 0% | 1 | 1% | .09 |
Abbreviations: BMI, body mass index; IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
P values were estimated using chi-square or Fisher’s exact tests for categorical variables and Kruskal–Wallis tests for continuous variables.
Other comorbidities included hypertension (n = 5), congenital heart disease (n = 3), chronic neurological disorder (n = 3), chronic kidney disease (n = 2), and malignancy (n = 1).